Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKQ0CA)

• Drug Name: bromoenol lactone Drug Info
• Synonyms: Bromoenol lactone; HELSS; 88070-98-8; 6-Btnpo; BTNP; C16H13BrO2; CHEMBL6206; BEL; 6-(Bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; Haloenol lactone suicide substrate; BYUCSFWXCMTYOI-ZRDIBKRKSA-N; (E)-6-(Bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-Pyran-2-one; (E)-6-(Bromomethylene)-3-(1-naphthalenyl)tetrahydro-2H-pyran-2-one; bromoenolactone; E-6-(Bromoethylene)tetrahydro-3-(1-naphthyl)-2H-pyran-2-one; 2H-Pyran-2-one, 6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-, (E)-; SR-01000075707; bromoenolactone

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5940264
  CAS Number: CAS 88070-98-8
  TTD Drug ID: DMKQ0CA

Molecule-Related Drug Atlas

Drug(s) Targeting Short transient receptor potential channel 5 (TRPC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 1358894	DM740BS	Depression	6A70-6A7Z	Phase 2	[5]
GFB-887	DM2IJWG	Diabetic nephropathy	GB61.Z	Phase 2	[6]
2-APB	DM9AKVR	Discovery agent	N.A.	Investigative	[7]
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[8]
lysophosphatidylcholine	DMOGFVH	Discovery agent	N.A.	Investigative	[8]
KB-R7943	DMMD5W3	Discovery agent	N.A.	Investigative	[9]
BTP2	DMNM63G	Discovery agent	N.A.	Investigative	[8]
ML204	DM15YL0	Discovery agent	N.A.	Investigative	[10]
(-)-englerin A	DMPQBWY	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[12]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[13]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[14]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[15]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[16]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[17]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[18]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[19]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[19]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[19]

Drug(s) Affected By 85/88 kDa calcium-independent phospholipase A2 (PLA2G6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[20]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[21]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[25]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[26]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[27]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[28]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[2]
Short transient receptor potential channel 5 (TRPC5)	TT32NQ1	TRPC5_HUMAN	Blocker (channel blocker)	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
85/88 kDa calcium-independent phospholipase A2 (PLA2G6)	OT5FL0WU	PLPL9_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5149).
• [2] Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43.
• [3] Bromoenol lactone inhibits voltage-gated Ca2+ and transient receptor potential canonical channels. J Pharmacol Exp Ther. 2011 Nov;339(2):329-40.
• [4] -Nicotinamide Adenine Dinucleotide (-NAD) Inhibits ATP-Dependent IL-1 Release from Human Monocytic Cells. Int J Mol Sci. 2018 Apr 10;19(4):1126. doi: 10.3390/ijms19041126.
• [5] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [6] Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney Int Rep. 2021 Jul 23;6(10):2575-2584.
• [7] Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol. 2005 Jun;145(4):405-14.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490).
• [9] The Na+/Ca2+ exchange inhibitor KB-R7943 potently blocks TRPC channels. Biochem Biophys Res Commun. 2007 Sep 14;361(1):230-6.
• [10] Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem. 2011 Sep 23;286(38):33436-46.
• [11] (-)-Englerin is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3787-91.
• [12] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [13] The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [16] The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
• [17] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
• [19] A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
• [20] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [21] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [22] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [23] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [24] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [25] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [26] Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):596-604. doi: 10.1158/1055-9965.EPI-04-0398.
• [27] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [28] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [29] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.